gendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint
, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods.
In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.
Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Irvine, California, United States, and Amsterdam, the Netherlands. For more information, please visit www.agendia.com.
For further information, please contact:
Ricochet Public Relations Page: 1 2 Related biology technology :1
Tel: +1 212 679 3300
. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium2
. EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study3
. Agendia Successfully Completes Bi-Annual FDA Inspection4
. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting5
. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists6
. Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint(R)7
. Agendia Raises US $23 Million in Series E Financing8
. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards9
. Agendia Opens CLIA-Registered U.S. Genomics Laboratory10
. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting11
. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference